Dulaglutide
Also known as: Trulicity
strong human dataFDA approved: Type 2 diabetes (Trulicity)
Published Dose Range
Low0.75 mg/week
Typical1.5-3 mg/week
High4.5 mg/week
FDA-approved weekly GLP-1 RA for T2D. Titrate 0.75 then 1.5 then 3 then 4.5 mg weekly, at least 4 weeks between steps.
Published Cycle Range
No published cycle data available.
Administration
Routessubcutaneous
FrequencyOnce weekly
Preferred timingSame day each week, any time
Consistent day of week.
Safety Profile
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Abdominal pain
- • Decreased appetite
Serious risks
- • Acute pancreatitis
- • Gallbladder disease
- • Kidney injury from dehydration
- • Thyroid C-cell tumors (boxed warning)
Drug interactions
- • Insulin/sulfonylureas (hypoglycemia risk)
Requires monitoring
- • HbA1c
- • Kidney function
Pregnancy / breastfeeding
Not recommended during pregnancy
Common Misconceptions
- Weight loss effect is smaller than Semaglutide or Tirzepatide at approved doses
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.